Comparing Enzymotec (ENZY) & Chemours Company (The) (CC)
Enzymotec (NASDAQ: ENZY) and Chemours Company (The) (NYSE:CC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
This is a summary of current recommendations and price targets for Enzymotec and Chemours Company (The), as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Chemours Company (The)||0||0||6||0||3.00|
Enzymotec currently has a consensus target price of $11.50, suggesting a potential upside of 3.14%. Chemours Company (The) has a consensus target price of $51.83, suggesting a potential downside of 7.36%. Given Enzymotec’s higher possible upside, research analysts plainly believe Enzymotec is more favorable than Chemours Company (The).
Chemours Company (The) pays an annual dividend of $0.12 per share and has a dividend yield of 0.2%. Enzymotec does not pay a dividend. Chemours Company (The) pays out 8.1% of its earnings in the form of a dividend.
Risk & Volatility
Enzymotec has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Chemours Company (The) has a beta of 3.6, suggesting that its stock price is 260% more volatile than the S&P 500.
Insider and Institutional Ownership
27.2% of Enzymotec shares are owned by institutional investors. Comparatively, 72.8% of Chemours Company (The) shares are owned by institutional investors. 1.1% of Chemours Company (The) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Enzymotec and Chemours Company (The)’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Enzymotec||$47.01 million||5.44||-$4.56 million||($0.29)||-38.45|
|Chemours Company (The)||$5.74 billion||1.80||$1.07 billion||$1.48||37.80|
Chemours Company (The) has higher revenue and earnings than Enzymotec. Enzymotec is trading at a lower price-to-earnings ratio than Chemours Company (The), indicating that it is currently the more affordable of the two stocks.
This table compares Enzymotec and Chemours Company (The)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Chemours Company (The)||4.96%||122.97%||6.77%|
Chemours Company (The) beats Enzymotec on 12 of the 15 factors compared between the two stocks.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Chemours Company (The) Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a North American provider of industrial chemicals used in gold production, oil and gas, water treatment and other industries. It delivers customized solutions with a range of industrial and specialty chemical products for markets, including plastics and coatings, refrigeration and air conditioning, industrial, mining and oil refining. Its products include titanium dioxide, refrigerants, industrial fluoropolymer resins and a portfolio of mining and industrial chemicals, including sodium cyanide. As of December 31, 2016, the Company operates 26 production facilities located in 10 countries.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.